Critic at Large

» regulation and cancer

Most Recent

image: Opinion: Improving FDA Evaluations Without Jeopardizing Safety and Efficacy

Opinion: Improving FDA Evaluations Without Jeopardizing Safety and Efficacy

By | February 1, 2017

What can be done to lower development costs and drug prices?

4 Comments

image: Pet Scans

Pet Scans

By , , and | April 1, 2016

Studying tumor development and treatment in dogs and cats, in parallel with research on rodents and humans, could improve the successful translation of new cancer drugs.

0 Comments

image: Getting Animal Research Right

Getting Animal Research Right

By | March 1, 2016

Regulatory and compliance expectations for animal-based research are demanding, while public and political scrutiny of animal research is rising.

2 Comments

image: Control ALT, Delete Cancer

Control ALT, Delete Cancer

By , , and | April 1, 2015

Treating cancer by shutting down the alternative lengthening of telomeres (ALT) pathway

1 Comment

image: The Challenges of Precision

The Challenges of Precision

By | April 1, 2015

Researchers face roadblocks to treating an individual patient’s cancer as a unique disease.

1 Comment

image: Fighting Cancer with Nanomedicine

Fighting Cancer with Nanomedicine

By | April 1, 2014

Nanotechnology-based therapeutics will revolutionize cancer treatment.

2 Comments

image: Cancer Clinical Trials of Tomorrow

Cancer Clinical Trials of Tomorrow

By | April 1, 2013

Advances in genomics and cancer biology will alter the design of human cancer studies.

0 Comments

image: DIYbio: Low Risk, High Potential

DIYbio: Low Risk, High Potential

By | March 1, 2013

Citizen scientists can inspire innovation and advance science education—and they are proving adept at self-policing.

5 Comments

image: Regulating Amateurs

Regulating Amateurs

By | March 1, 2013

How should the government ensure the safety and responsibility of do-it-yourself biologists?

2 Comments

image: Regulations for Biosimilars

Regulations for Biosimilars

By | June 1, 2012

As biologic drug patents begin to expire, generic versions will hit the market—but how will they be regulated?

2 Comments

Popular Now

  1. Henrietta Lacks’s Family Seeks Compensation
  2. Broad Wins CRISPR Patent Interference Case
    Daily News Broad Wins CRISPR Patent Interference Case

    The USPTO’s Patent Trial and Appeal Board has ruled in favor of the Broad Institute of MIT and Harvard retaining intellectual property rights covered by its patents for CRISPR gene-editing technology.

  3. Humans Never Stopped Evolving
    Features Humans Never Stopped Evolving

    The emergence of blood abnormalities, an adult ability to digest milk, and changes in our physical appearance point to the continued evolution of the human race.

  4. Abundant Sequence Errors in Public Databases
Business Birmingham